Please check your internet connection and try again.
# Durveqtix gene therapy
## Overview
Durveqtix is a gene therapy indicated for the treatment of patients 12 years of age and older with Hemophilia A. It is a one-time intravenous infusion that delivers the gene for human coagulation factor VIII.
## Primary Indications
Treatment of Hemophilia A in patients 12 years of age and older.
## Adult Dosing
A single intravenous infusion of Durveqtix at a dose of 6x10^12 vector genomes per kilogram (vg/kg).
## Pediatric Dosing
For patients 12 to <18 years of age, a single intravenous infusion of Durveqtix at a dose of 6x10^12 vector genomes per kilogram (vg/kg).
## Dose Adjustments
No dose adjustments are specified based on organ function (renal or hepatic).
## Contraindications
* Known history of hypersensitivity to Durveqtix or any of its components.
* Patients with active or uncontrolled infections due to the risk of systemic inflammation and potential for adverse reactions.
## Adverse Effects
The most commonly reported adverse reactions (≥5% of patients) include elevated liver enzymes (AST, ALT), nausea, headache, infusion-related reactions, increased troponin I, and decreased haptoglobin.
## Key Drug Interactions
No specific drug interactions have been identified in clinical trials. However, caution should be exercised if co-administered with medications that may affect liver function or the immune system.
## Monitoring
* Liver function tests (AST, ALT, bilirubin) should be monitored regularly post-infusion (e.g., at baseline, 1 week, 2 weeks, 1 month, 3 months, 6 months, and 12 months).
* Monitor for signs and symptoms of hypersensitivity reactions during and after infusion.
* Monitor for signs of immune responses to the AAV capsid.
* Monitor haptoglobin and troponin I levels post-infusion.
## Clinical Pearls
* Durveqtix is a one-time treatment; re-administration is generally not recommended due to the potential for an immune response against the adeno-associated virus (AAV) vector.
* Patients should be monitored closely for liver enzyme elevations. If elevations occur, management may involve corticosteroids.
* Discuss the potential risks and benefits of this gene therapy with patients, particularly regarding long-term efficacy and potential immune responses.
***
*Disclaimer: This information is intended for healthcare professionals. Always consult the most current prescribing information and local guidelines for definitive guidance, as drug information can change. The information provided here is not a substitute for professional medical judgment.*
